BioSpace News Archive

Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the closing of its previously announced underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $5.75 per share, including 3,260,869 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares

Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, reported that on March 22, 2021, the Company granted non-qualified stock options to purchase an aggregate of 300,000 shares of the Company’s common stock to its newly hired President, Dr. Rand Sutherland.

Therap Services, the leading software solution for HIPAA-compliant electronic documentation for Home and Community-based Services (HCBS) and Long-Term Services and Supports (LTSS) providers, has interfaced with HHA Exchange for service providers in New Jersey.

Diversified Medical Healthcare (DMH), a holding company with four subsidiary healthcare companies, Premier Medical Laboratory Services (PMLS), CPT Medical, OnGen, and Vessel Medical, has provided leading-edge solutions to combat COVID-19 nationally, addressing supply chain gaps and infrastructure restrictions caused by the virus.

Data presented at ENDO 2021 demonstrate clinically relevant weight loss, without weight regain, in people treated with semaglutide 2.4 mg vs placebo in combination with lifestyle intervention

RiverVest Venture Partners, a leading venture capital firm, announced today the closing of its RiverVest Venture Fund V, L.P. (“Fund V”), with $275 million of capital commitments in an oversubscribed fundraise.

Aber Instruments (Aber), a world-leading manufacturer of on-line biomass monitoring technology, is delighted to announce its new Futura neotf single-use biomass sensor is available.

Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the fiscal year ended December 31, 2020

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced its financial results for the fourth quarter and full year 2020 and provided an overview of recent business highlights.

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and fourth quarter and full year 2020 financial results. “